Why the study?
Does a fully phosphorylcholine-coated closed circuit with low systemic heparinization improve clinical outcomes and reduce bleeding compared to heparin-coated circuits in patients undergoing coronary revascularization?
Does a fully phosphorylcholine-coated closed circuit with low systemic heparinization improve clinical outcomes and reduce bleeding compared to heparin-coated circuits in patients undergoing coronary revascularization?
A phosphorylcholine-coated closed circuit allows for a safe reduction in systemic heparinization during cardiopulmonary bypass, resulting in reduced postoperative bleeding and better platelet preservation.
May support reduced heparinization with phosphorylcholine coating in CPB; leaves open confirmation in randomized trials.
Cardiopulmonary bypass with heparin-bonded circuits reduces systemic heparinization which is associated to a better clinical outcome in cardiac operations. In the present study, a novel biocompatible treatment, based on a phosphorylcholine coating without heparin, has been used to reduce systemic heparinization during cardiopulmonary bypass. Sixty patients underwent coronary revascularization with a fully phosphorylcholine-coated circuit. The circuit was entirely closed; suctions from the field were separated during the cardiopulmonary bypass time. A low systemic heparinization protocol based on half the loading dose of heparin (150 IU/kg) and a target activated clotting time of 320 seconds was applied. No thrombus formation inside the extracorporeal circulation circuit occurred; in-hospital mortality was absent. One patient (1.6%) had a postoperative myocardial infarction and 2 (3.3%) were surgically revised due to bleeding. Homologous blood transfusion rate was 11.6%, postoperative bleeding was 310 +/- 136 ml. If compared to patients treated with heparin-coated circuits and low systemic heparinization, these patients have better platelet count preservation and lower postoperative bleeding. The low thrombogenicity of phosphorylcholine-treated surfaces, despite the absence of surface-immobilized heparin, allows a safe reduction of systemic heparinization in the setting of an ECMO-like intraoperative cardiopulmonary - bypass. This intraoperative ECMO approach offers promising results in terms of clinical outcome after coronary revascularization operations.
No takes yet. Share an insight, caveat, or question.
Ranucci et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: